

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Proposal for resolution on reduction of the share capital

The board of Immunovia AB (publ), Reg. No. 556730-4299, proposes that the annual general meeting on 19 June 2024 resolves to reduce the company's share capital by SEK 905,749.96 for allocation to non-restricted equity and without cancellation of shares. The reason for the board's proposal for the reduction of the company's share capital for allocation to non-restricted equity is to improve the ratio between the share capital and non-restricted equity.

Pursuant to Chapter 20, Section 13 of the Swedish Companies Act (2005:551) (*Sw. Aktiebolagslagen*), the board states the following. The decision to reduce the company's share capital in accordance with the proposal can be carried out without permission from the Swedish Companies Registration Office (*Sw. Bolagsverket*) or a general court since the company intends to carry out a rights issue of units, which means that neither the company's restricted equity nor the share capital together will decrease. The board's proposal for resolution on approval of the board's resolution on a rights issue of units is set out in item 14 on the agenda for the annual general meeting.

The effect of the board's proposal to reduce the share capital in accordance with this proposal is that the share capital and restricted equity will be reduced by SEK 905,749.96 to SEK 1,358,624.94, whereby the quota value of the share will decrease from SEK 0.05 to SEK 0.03. In connection with the registration of the reduction with the Swedish Companies Registration Office, a share capital increase corresponding to at least the proposed reduction will also be registered, resulting in that neither the company's restricted equity nor the share capital decreases.

The resolution of a reduction of the share capital presupposes and is conditional upon that the board's resolution on the rights issue of units, as set out in item 14 on the agenda for the annual general meeting, is approved and that the rights issue is subscribed to such an extent that the share capital after the rights issue amounts to at least SEK 2,264,374.90.

For a valid resolution, the proposal must be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the general meeting.

The company's CEO shall be authorized to make such minor formal adjustments to the resolution that may be required in connection with registration with the Swedish Companies Registration Office (*Sw. Bolagsverket*).

Lund on 20 May 2024

The Board of Directors of Immunovia AB (publ)